

Special Issue

Elimination of Viral Hepatitis: Improving Diagnosis, Treatment and Surveillance

Message from the Guest Editors

This Special Edition of *Viruses* will explore key challenges in the global elimination of viral hepatitis. It will particularly focus on three broad areas of research that are all needed to reduce the global burden of viral hepatitis. First, it will report innovations in diagnostics to improve and simplify the process of obtaining a reliable, low-cost, and quick diagnosis. Second, it will explore novel pathways that link people to care and treatment, making treatment services acceptable and reducing stigma. Third, it will examine surveillance systems and interventions in healthcare data to monitor progress toward elimination. This edition will encourage submissions from cross-disciplines including epidemiology, clinical, health services, and social research focused on viral hepatitis.

Guest Editors

Dr. Joseph Doyle

The Alfred, Monash University and Burnet Institute, Melbourne, Australia

Dr. Amanda Wade

1. Disease Elimination, Burnet Institute, Melbourne, Australia
2. Department of Infectious Diseases, Barwon Health, Geelong, Australia.

Deadline for manuscript submissions

closed (30 September 2022)



Viruses

an Open Access Journal
by MDPI

Impact Factor 3.8
CiteScore 7.3
Indexed in PubMed



mdpi.com/si/104305

Viruses
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
viruses@mdpi.com

[mdpi.com/journal/
viruses](https://mdpi.com/journal/viruses)





Viruses

an Open Access Journal
by MDPI

Impact Factor 3.8
CiteScore 7.3
Indexed in PubMed



[mdpi.com/journal/
viruses](https://mdpi.com/journal/viruses)



About the Journal

Message from the Editor-in-Chief

Viruses (ISSN 1999-4915) is an open access journal which provides an advanced forum for studies of viruses. It publishes reviews, regular research papers, communications, conference reports and short notes. Our aim is to encourage scientists to publish their experimental and theoretical results in as much detail as possible. There is no restriction on the length of the papers. The full experimental details must be provided so that the results can be reproduced. We also encourage the publication of timely reviews and commentaries on topics of interest to the virology community and feature highlights from the virology literature in the 'News and Views' section.

Electronic files or software regarding the full details of the calculation and experimental procedure, if unable to be published in a normal way, can be deposited as supplementary material.

Editor-in-Chief

Dr. Eric O. Freed

Director, HIV Dynamics and Replication Program, Center for Cancer Research, National Cancer Institute, Frederick, MD 21702-1201, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, PubAg, AGRIS, and other databases.

Journal Rank:

JCR - Q2 (Virology) / CiteScore - Q1 (Infectious Diseases)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 16.1 days after submission; acceptance to publication is undertaken in 2.6 days (median values for papers published in this journal in the first half of 2024).